FSE$QGEN
QIAGEN · Q3 2025 earnings
Q3 2025 earnings · · After market close · Investor relations
Briefing
QIAGEN Q3 2025: $532.6M net sales (+6%) with EPS of $0.60 on strong margins
QIAGEN reported third quarter 2025 net sales of $532.6 million, up 6% from $501.9 million in Q3 2024, with gross profit rising to $331.3 million on a 62.2% gross margin. Net income was $130.0 million, or $0.60 per diluted share, compared to $98.1 million and $0.44 per share a year ago. Operating income increased to $129.2 million from $112.1 million. Nine-month net sales reached $1,549.6 million with net income of $317.1 million ($1.45 diluted EPS), a sharp improvement from a net loss in the prior-year period. Cash and cash equivalents grew to $1.36 billion at quarter end. The company completed the Genoox acquisition in May 2025 for AI-powered clinical genomics software. Management noted continued momentum in Sample to Insight solutions across life sciences and molecular diagnostics end markets.
- Q3 net sales rose 6% to $532.6M; gross profit was $331.3M with a 62.2% gross margin.
- Q3 net income was $130.0M with diluted EPS of $0.60 versus $98.1M and $0.44 in Q3 2024.
- Nine-month net sales were $1,549.6M with net income of $317.1M ($1.45 diluted EPS).
- Cash and cash equivalents increased to $1.36B at September 30, 2025.
- Genoox acquisition closed in May 2025, expanding AI-powered clinical genomics capabilities.
Headline financials
Revenue & EPS history
QIAGEN · Revenue · Quarterly
$533M
Revenue by segment
QIAGEN · $847M total across 4 segments · Q1 2026
- Consumables and related revenues$445M—52.5%
- Diagnostic solutions$185M—21.8%
- Sample technologies$170M—20.0%
- Instruments$47.5M—5.6%
Forward guidance
QIAGEN continues to execute on its Sample to Insight strategy with improving profitability and strong cash generation, supported by the Genoox acquisition and ongoing share repurchases under its capital allocation framework.
Tailwinds
- Double-digit operating income growth with expanding margins in Q3.
- Nine-month operating cash flow of $466M supports continued investment and capital returns.
Headwinds
- Restructuring and integration costs remain elevated at $32.0M for the nine-month period.
- Interest expense and FX hedging volatility continue to affect other income.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2025
+0.5%
Avg return
Earnings day
+1.4%
Avg return
5 days after
+3.0%
Avg return
30 days after
50%
32 / 64 earnings
Positive
+16.1%
Q2 2016
Best reaction
-6.2%
Q3 2015
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.3% | -13.5% | -3.8% | |
| Q4 2025 | -0.9% | -1.2% | -13.8% | |
| Q3 2025 | -3.6% | -2.2% | +6.5% | |
| Q2 2025 | -3.1% | +3.1% | +0.1% | |
| Q1 2025 | +1.7% | -0.7% | +10.3% | |
| Q4 2024 | -2.1% | -7.6% | -8.3% | |
| Q3 2024 | +0.4% | +0.2% | -1.2% | |
| Q2 2024 | +2.4% | +0.4% | +2.2% | |
| Q1 2024 | +1.6% | +3.2% | +2.2% | |
| Q4 2023 | +3.1% | +5.5% | +5.5% | |
| Q3 2023 | +3.7% | +8.6% | +14.2% | |
| Q2 2023 | -1.1% | -3.3% | -6.9% | |
| Q1 2023 | +3.8% | +3.9% | +4.8% | |
| Q4 2022 | +0.1% | -0.2% | -7.1% | |
| Q3 2022 | +3.8% | +12.9% | +14.6% | |
| Q2 2022 | +1.9% | +4.7% | +1.0% | |
| Q1 2022 | +0.3% | +0.4% | +1.0% | |
| Q4 2021 | +0.8% | -3.1% | -11.3% | |
| Q3 2021 | +0.9% | -1.5% | -1.7% | |
| Q2 2021 | +2.3% | +1.7% | +7.5% | |
| Q1 2021 | -0.4% | -1.0% | -2.2% | |
| Q4 2020 | -1.4% | +0.4% | -12.9% | |
| Q3 2020 | -1.1% | -3.7% | -4.1% | |
| Q2 2020 | -3.8% | -3.3% | -4.0% | |
| Q1 2020 | +1.8% | +2.7% | +4.9% | |
| Q4 2019 | +3.8% | +5.7% | +23.7% | |
| Q3 2019 | +2.9% | +6.1% | +47.7% | |
| Q2 2019 | -1.6% | -3.0% | -9.8% | |
| Q1 2019 | -5.5% | -5.7% | -0.5% | |
| Q4 2018 | -0.9% | -0.3% | +6.7% | |
| Q3 2018 | +4.7% | +8.4% | +3.0% | |
| Q2 2018 | +4.1% | +5.4% | +8.1% | |
| Q1 2018 | +4.0% | +5.0% | +11.2% | |
| Q4 2017 | +0.6% | -4.9% | -3.2% | |
| Q2 2017 | -3.4% | -4.0% | -8.1% | |
| Q1 2017 | +2.1% | +5.6% | +11.6% | |
| Q4 2016 | +1.1% | +0.4% | +0.9% | |
| Q3 2016 | +7.6% | +12.6% | +11.8% | |
| Q2 2016 | +16.1% | +15.8% | +15.5% | |
| Q1 2016 | -4.0% | — | — | |
| Q4 2015 | -2.0% | — | — | |
| Q3 2015 | -6.2% | — | — | |
| Q2 2015 | +2.2% | — | — | |
| Q1 2015 | -0.2% | — | — | |
| Q4 2014 | -1.2% | — | — | |
| Q3 2014 | +1.0% | — | — | |
| Q2 2014 | -0.5% | — | — | |
| Q4 2013 | -3.7% | — | — | |
| Q2 2013 | +1.1% | — | — | |
| Q1 2013 | -3.7% | — | — | |
| Q4 2012 | +6.6% | — | — | |
| Q3 2012 | +3.8% | — | — | |
| Q2 2012 | -0.2% | — | — | |
| Q1 2012 | -0.2% | — | — | |
| Q4 2011 | -1.0% | — | — | |
| Q3 2011 | -1.8% | — | — | |
| Q2 2011 | +1.4% | — | — | |
| Q1 2011 | +1.4% | — | — | |
| Q4 2008 | -0.1% | — | — | |
| Q4 2010 | -0.1% | — | — | |
| Q4 2009 | -0.1% | — | — | |
| Q3 2010 | -1.7% | — | — | |
| Q1 2010 | -1.2% | — | — | |
| Q2 2010 | -1.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro